Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from FDA

Cheese recalled over potential serious health risk

The recalled cheese was sold in Oregon

The Independent UK · Nov 18, 2025

I treat menopause and its symptoms, and hormone replacement therapy can help – here’s the science behind the FDA’s decision to remove warnings

For more than 20 years, hormone therapy for menopause has carried a warning label from the Food and Drug Administration describing the medication’s risk of serious harms – namely, cancer, cardiovascular disease and possibly dementia.

The Conversation · Nov 18, 2025

10 Common Baby Products Now Under FDA Scrutiny

Image source: shutterstock.com

Kids Ain't Cheap · Nov 18, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

With $199 Price, Ozempic Prescriptions Expected to Soar — Experts Warn of Risks

Novo Nordisk's new $199 offer for Ozempic and Wegovy aims to improve access for obesity and diabetes treatments, but experts warn of potential serious side effects.

International Business Times UK · Nov 18, 2025

Dietary supplements recalled nationwide after 11 people sickened with salmonella

Three people have been hospitalized amid the latest salmonella outbreak

The Independent UK · Nov 15, 2025

From 15 to 23 Cases: ByHeart Infant Formula Outbreak Shows How Quickly Safety Signals Escalate

The ByHeart infant formula botulism outbreak has grown to 23 cases across 13 states, raising urgent questions about food safety oversight and federal preparedness.

International Business Times UK · Nov 15, 2025

These 6 Popular Restaurants Don’t Use Real Cheese

You grab your favorite cheeseburger from a drive-thru window. That melty, gooey slice on top looks perfect. But here’s the thing: it might not be real cheese. Yeah, you read that right.

Grocery Coupon Guide · Nov 15, 2025

Read news from The Economist, FT, and more,
with one subscription

Turmoil and tensions at FDA after dramatic exit of top drug regulator

Scramble to find replacement for George Tidmarsh shines light on dysfunction at US regulatory agency

The Guardian - US · Nov 15, 2025

This new eye drop could help adults with age-related vision issues

The drops specifically combat presbyopia, an age related blurry vision issue.

Axios · Nov 15, 2025

FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths

The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year

The Independent UK · Nov 14, 2025

Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since

Eli Lilly's blockbuster drug Zepbound could be getting a big new customer: Medicare. See the implications of the company's recent deal with President Trump.

MarketBeat · Nov 14, 2025

Merck Makes Big Bet On Flu Protection With Cidara Buyout

Merck Co. Inc. (NYSE:MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ:CDTX) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.

Benzinga · Nov 14, 2025

Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight?

Cidara Therapeutics Inc. (NASDAQ:CDTX) shares are trending on Friday.

Benzinga · Nov 14, 2025

A closer look at the unapproved peptide injections promoted by influencers and celebrities

Unapproved peptide drugs have become a trendy new approach to building muscle, smoothing wrinkles and trying to live longer

The Independent UK · Nov 14, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK · Nov 14, 2025

Americans are injecting themselves with unproven peptides sold by influencers and RFK Jr. allies

More Americans are turning to peptides for muscle building, skin rejuvenation, and to try and live longer even though the substances aren’t FDA approved

Grocery Coupon Guide · Nov 13, 2025

10 Grocery Items That Are Only Expensive Because of Marketing

We’ve all been there: you’re staring at two identical-looking products on the shelf, but one costs twice as much. The expensive one boasts about its “artisan” origins, “premium” ingredients, or “doctor-recommended” status. But what are you really paying for? Often, it’s not a better product—it’s just better marketing. Brands spend…

Barchart · Nov 13, 2025

Should You Buy the Dip in Intellia Therapeutics Stock?

A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?

The Conversation · Nov 13, 2025

What’s a ‘black box’ warning? A pharmacologist explains how these labels protect patients

A “black box” warning on a health product sounds pretty scary – maybe even more so when it’s suddenly being taken off the packaging.

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily · Nov 13, 2025

NMN Supplements for Peak Performance, Prevention & Longevity

Discover how Omre's NMN + Resveratrol supplement boosts cellular energy, recovery, and longevity — the doctor-formulated edge for peak performance and healthy aging.

MarketBeat · Nov 12, 2025

3 Beaten-Down Stocks With Rebound Potential This Earnings Season

These firms present at least a modest risk/reward profile, but could be preparing for a share price turnaround depending upon how earnings season plays out.

Benzinga · Nov 12, 2025

FDA Names Veteran Oncologist Richard Pazdur To Lead Drug Center After Ethics Scandal Ousts George Tidmarsh

The U.S. Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur as the new head of its drug center, succeeding Dr. George Tidmarsh, who was removed following an ethics complaint just months after his appointment.

Reason · Nov 12, 2025

The Perils of Viewing Psilocybin Strictly As a Psychiatric Medication

The most common uses of "magic mushrooms" will never gain FDA approval.

International Business Times UK · Nov 11, 2025

15 Sick Infants, One Brand: Is ByHeart's Organic Promise a Dangerous Illusion?

ByHeart's infant formula recall follows a botulism outbreak that hospitalized 15 babies across 12 states. The case raises questions about boutique branding, regulatory oversight, and consumer trust.

Benzinga · Nov 11, 2025

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

enGene Holdings Inc. (NASDAQ:ENGN) stock is edging higher on Tuesday, with a session volume of 18.62 million compared to an average volume of 266.85 thousand, as per data from Benzinga Pro.

Barchart · Nov 11, 2025

Is This Beaten-Down Cathie Wood Stock Still a Buy?

Intellia’s shares plunged 23% after its Q3 results showed a pipeline setback. Nonetheless, Cathie Wood’s stake in the company is expanding.

1 … 89 90 91 92

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.